Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2461 to 2475 of 7683 results

  1. Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia [ID6156]

    Awaiting development [GID-TA11087] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Semaglutide for treating non-alcoholic steatohepatitis with significant liver fibrosis ID6458

    Awaiting development [GID-TA11477] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Acalabrutinib with venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia ID6232

    Awaiting development [GID-TA11230] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Durvalumab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung cancer [ID6404]

    Awaiting development [GID-TA11515] Expected publication date: 09 January 2025

    Technology appraisal guidance
    Awaiting development

  5. Avacincaptad pegol for treating geographic atrophy caused by age-related macular degeneration [ID6401]

    Awaiting development [GID-TA11511] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Artificial intelligence technologies to help detect fractures on X-rays in urgent care

    In development [GID-HTE10044] Expected publication date: 14 January 2025

    Health technology evaluations
    In development

  7. Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen ID6462

    In development [GID-TA11602] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy [ID5100]

    In development [GID-TA10999] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Falls: assessment and prevention in older people and people 50 and over at higher risk (update)

    In development [GID-NG10228] Expected publication date: 26 March 2025

    NICE guideline
    In development

  10. Falls: assessment and prevention in older people and people 50 and over at higher risk (update): draft guidance consultation

    We are listening to your views on this NICE guideline. Comments close 28 November 2024.

    NICE guideline
    In consultation

  11. Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments [ID6226]

    Awaiting development [GID-TA11231] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 20 November 2024.

    Technology appraisal guidance
    In consultation

  13. Digital technologies for assessing attention deficit hyperactivity disorder (ADHD) (DG60)

    Evidence-based recommendations on digital technologies for assessing attention deficit hyperactivity disorder (ADHD)

    Diagnostics guidance
    Published
    21 October 2024
    View recommendations

    Sections for DG60

  14. Tirzepatide for managing overweight and obesity [ID6179]

    In development [GID-TA11156] Expected publication date: 19 December 2024

    Technology appraisal guidance
    In development

  15. Dupilumab for treating eosinophilic oesophagitis in children 1 to 11 years ID 6492

    Awaiting development [GID-TA11383] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development